Sleep Apnea dev Invicta Medical raises $21m
Sleep apnea device developer Invicta Medical has raised approximately $21 million in a new round of equity financing, according to an SEC filing posted this week. The Palo Alto, Calif.-based company, founded in 2013, has not yet revealed the technology behind its development but claims that its solution to treating obstructive sleep apnea is non-invasive, customizable to meet patient needs and affordable, according to its website. The company has not yet officially stated how it plans to spend funds raised in the round. The round was joined by 6 anonymous investors, with the first sale in the round dated on December 20, 2017, according to the SEC filing. The post Sleep Apnea dev Invicta Medical raises $21m appeared first on MassDevice.
Conclusions: The confounding factors present in the triad of OSAS, COPD, and obesity prevented the perception of increased daytime sleepiness and high risk for OSAS. We observed no worsening of dyspnea perception or quality of life.RESUMO Objetivo: Avaliar se a presen ça de síndrome da apneia obstrutiva do sono (SAOS) modifica a percepção de queixas respiratórias e de qualidade de vida em pacientes com DPOC por meio de questionários específicos, além de verificar se escalas de sonolência diurna e de rastreamento para SAOS podem ser empregadas na tríade SA...
Condition: Obstructive Sleep Apnea Intervention: Other: CSR remote monitoring Sponsors: Groupe Medical de Pneumologie, Polyclinique Saint-Laurent; Slb Pharma; Vitalaire; Agence Régionale de Santé - Bretagne; ResMed Enrolling by invitation
ConclusionsCPAP can improve autonomic activity, which might be one mechanism to reduce the risk of cardiovascular diseases in OSA.
This study investigated the influence of rivaroxaban on cardiac remodeling caused by intermittent hypoxia (IH). Male C57BL/6J mice were exposed to IH (repeated cycles of 5% oxygen for 1.5 min followed by 21% oxygen for 5 min) for 28 days with/without rivaroxaban (12 mg/kg/day) or FSLLRY, a protease-activated receptor (PAR)-2 antagonist (10 μg/kg/day). IH caused endothelial cell degeneration in the small arteries of the right atrial myocardium and increased the level of %fibrosis and 4-hydroxy-2-nonenal protein adducts in the left ventricular myocardium. IH also increased the expression of PAR-2 as we...
Early intervention to treat sleep disorders such as obstructive sleep apnea may help prevent or delay Alzheimer’s disease.
ConclusionThe significant prevalence of POAG among OSA sufferers suggests need for preoperative consultations from an ophthalmologist to determine eye health and possibly an anesthesiologist to avoid potential vision loss.
Conclusion: This study shows that the severity of OSA is not associated with the recurrence of AF after catheter ablation in Korean patients. Treatment of OSA for the sole indication of lowering AF recurrence may need to be reconsidered.Pulse 2018;6:103 –111
To develop and test a screening tool based on the OSA-18 questionnaire for triage of referrals for sleep-disordered breathing (SDB) in children.
ConclusionsAmbient sounds recorded from a smartphone during sleep can identify apnea and abnormal breathing verified on PSG. Future studies should determine if this approach may facilitate early screening of SDB to identify at-risk patients for definitive diagnosis and therapy.Clinical trialsNCT03288376;clinicaltrials.org
CONCLUSION: Prevalence and major risk factors within the UAE are similar to those in other countries. Sleeping disorders and snoring campaigns and management facilities should be considered to raise the awareness about these issues and manage their risk factors.